Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. The study aims to establish the safety and feasibility of the use of FoTv vs placebo in 66 total subjects.
Description: The safety of the study medication will be assessed by number and severity of participants with treatment-related adverse events as assessed by Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 July 2017 between the two study arms.
Measure: Adverse Events Time: 2 monthsDescription: The safety of the study medication will also assessed by a comparison of the serum creatinine level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients)
Measure: Creatinine Time: 2 monthsDescription: The safety of the study medication will also assessed by a comparison of the aspartate transaminase of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients)
Measure: Aspartate transaminase Time: 2 monthsDescription: The safety of the study medication will also assessed by a comparison of the alanine transaminase of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients)
Measure: Alanine transaminase Time: 2 monthsDescription: The safety of the study medication will also assessed by a comparison of the prothrombin time of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients)
Measure: Prothrombin time Time: 2 monthsDescription: The safety of the study medication will also assessed by a comparison of the Partial Thromboplastin Time of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients)
Measure: Partial Thromboplastin Time Time: 2 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by duration of COVID-19 acute viral illness (as measured by fever and self-reported symptom scores)
Measure: Duration of viral illness Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by hospitalization rate.
Measure: Hospitalization rate Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by ICU admission rate.
Measure: ICU admission Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by maximum ventilatory requirement during hospitalization, if applicable.
Measure: Ventilatory requirement Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the lymphocyte count of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients).
Measure: Lymphocyte count Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the neutrophil count of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients).
Measure: Neutrophil count Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum ferritin level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients).
Measure: Ferritin Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum d-dimer level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients).
Measure: D-Dimer Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum Lactate Dehydrogenase level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients).
Measure: Lactate Dehydrogenase Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum C-Reactive Protein level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients).
Measure: C-Reactive Protein Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum troponin level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients).
Measure: Troponin Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by changes in the SARS CoV-2 viral loads among mid-turbinate nasal swabs taken on days 0, 4, 7 and 14.
Measure: Mid-turbinate nasal swabs Time: 6 monthsDescription: A secondary exploratory objective will be to evaluate immune response to FoTv in the setting of COVID-19 infection by comparing the PBMC transcriptome between subjects in each of the two arms.
Measure: Peripheral Blood Mononuclear Cell (PBMC) immune profiling Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports